Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.

Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D.

Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091-3. doi: 10.1016/j.ygyno.2020.01.038. [Epub ahead of print]

PMID:
32044108
2.

Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.

Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ.

ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.

3.

Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review.

Elsamadicy EA, Schneiter MK, Hull PC, Khabele D.

Hum Vaccin Immunother. 2019;15(7-8):1851-1855. doi: 10.1080/21645515.2019.1619405. Epub 2019 Jun 11.

4.

Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy.

Gupta V, Yull F, Khabele D.

Cancers (Basel). 2018 Sep 29;10(10). pii: E366. doi: 10.3390/cancers10100366. Review.

5.

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer.

Jewell A, McMahon M, Khabele D.

Cancers (Basel). 2018 Sep 1;10(9). pii: E296. doi: 10.3390/cancers10090296. Review.

6.

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.

Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.

7.

Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.

Beeghly-Fadiel A, Wilson AJ, Keene S, El Ramahi M, Xu S, Marnett LJ, Fadare O, Crispens MA, Khabele D.

J Ovarian Res. 2018 Feb 27;11(1):17. doi: 10.1186/s13048-018-0389-9.

8.

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.

Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.

Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.

9.

Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines.

Foxx AM, Zhu Y, Mitchel E, Nikpay S, Khabele D, Griffin MR.

J Adolesc Health. 2018 Feb;62(2):170-175. doi: 10.1016/j.jadohealth.2017.08.027. Epub 2017 Nov 22.

10.

Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors.

Choi H, Ignacio RMC, Lee ES, Wilson AJ, Khabele D, Son DS.

Immune Netw. 2017 Apr;17(2):121-127. doi: 10.4110/in.2017.17.2.121. Epub 2017 Apr 20.

11.

Blood type, ABO genetic variants, and ovarian cancer survival.

Cozzi GD, Levinson RT, Toole H, Snyder MR, Deng A, Crispens MA, Khabele D, Beeghly-Fadiel A.

PLoS One. 2017 Apr 27;12(4):e0175119. doi: 10.1371/journal.pone.0175119. eCollection 2017. Erratum in: PLoS One. 2017 May 30;12 (5):e0178965.

12.

Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics.

Sanderson M, Canedo JR, Khabele D, Fadden MK, Harris C, Beard K, Burress M, Pinkerton H, Jackson C, Mayo-Gamble T, Hargreaves MK, Hull PC.

BMC Public Health. 2017 Feb 2;17(1):158. doi: 10.1186/s12889-017-4094-1.

13.

Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.

Cozzi GD, Samuel JM, Fromal JT, Keene S, Crispens MA, Khabele D, Beeghly-Fadiel A.

BMC Cancer. 2016 Aug 8;16:612. doi: 10.1186/s12885-016-2660-z.

14.

Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.

Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D.

Gynecol Oncol. 2016 Oct;143(1):143-151. doi: 10.1016/j.ygyno.2016.07.088. Epub 2016 Jul 19.

15.

Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy.

Jiang X, Li H, Zhao P, Xie J, Khabele D, Xu J, Gore JC.

Neoplasia. 2016 Jun;18(6):387-97. doi: 10.1016/j.neo.2016.04.006.

16.

Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing.

Nielsen TA, David SN, Desouki MM, Crispens MA, Khabele D.

Gynecol Oncol Rep. 2015 Sep 25;14:20-2. doi: 10.1016/j.gore.2015.09.003. eCollection 2015 Nov.

17.

Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.

Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F.

Mol Cancer. 2015 Nov 9;14:192. doi: 10.1186/s12943-015-0463-5.

18.

Results of a Health Education Message Intervention on HPV Knowledge and Receipt of Follow-up Care among Latinas Infected with High-risk Human Papillomavirus.

Sanderson M, Khabele D, Brown CL, Harbi K, Alexander LR, Coker AL, Fernandez ME, Brandt HM, Fadden MK, Hull PC.

J Health Care Poor Underserved. 2015 Nov;26(4):1440-55. doi: 10.1353/hpu.2015.0131.

19.

Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P.

Cancer Lett. 2015 Nov 1;368(1):79-87. doi: 10.1016/j.canlet.2015.07.032. Epub 2015 Jul 30.

20.

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.

Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D.

J Ovarian Res. 2015 Jul 28;8:46. doi: 10.1186/s13048-015-0177-8.

21.

Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer.

Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D.

Oncotarget. 2015 Aug 28;6(25):21353-68.

22.

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

Stewart ML, Tamayo P, Wilson AJ, Wang S, Chang YM, Kim JW, Khabele D, Shamji AF, Schreiber SL.

Cancer Res. 2015 Jul 15;75(14):2897-906. doi: 10.1158/0008-5472.CAN-14-2860. Epub 2015 May 12.

23.

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.

Carrillo AM, Hicks M, Khabele D, Eischen CM.

Mol Cancer Res. 2015 Aug;13(8):1197-205. doi: 10.1158/1541-7786.MCR-15-0089. Epub 2015 May 11.

24.
25.

Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?

Desouki MM, Khabele D, Crispens MA, Fadare O.

Int J Gynecol Pathol. 2015 Jan;34(1):19-24. doi: 10.1097/PGP.0000000000000105.

PMID:
25473748
26.

Preferential effect of akt2-dependent signaling on the cellular viability of ovarian cancer cells in response to EGF.

Khabele D, Kabir SM, Dong Y, Lee E, Rice VM, Son DS.

J Cancer. 2014 Sep 5;5(8):670-8. doi: 10.7150/jca.9688. eCollection 2014.

27.

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.

Khabele D.

Front Oncol. 2014 May 20;4:111. doi: 10.3389/fonc.2014.00111. eCollection 2014. Review.

28.

Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.

Desouki MM, Kallas SJ, Khabele D, Crispens MA, Hameed O, Fadare O.

Int J Gynecol Pathol. 2014 May;33(3):274-81. doi: 10.1097/PGP.0b013e31829040b5.

29.

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.

Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.

30.

HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach.

Hull PC, Williams EA, Khabele D, Dean C, Bond B, Sanderson M.

Gynecol Oncol. 2014 Mar;132 Suppl 1:S13-20. doi: 10.1016/j.ygyno.2014.01.046. Epub 2014 Jan 31.

31.

Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH.

Gynecol Oncol. 2014 May;133(2):353-61. doi: 10.1016/j.ygyno.2013.12.039. Epub 2014 Jan 7. Review.

32.

Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells.

Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D, Son DS.

J Cancer. 2013 Sep 27;4(8):671-8. doi: 10.7150/jca.7118. eCollection 2013.

33.

Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.

Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D.

J Ovarian Res. 2013 Sep 10;6(1):63. doi: 10.1186/1757-2215-6-63.

34.

An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.

Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL.

Cell. 2013 Aug 29;154(5):1151-1161. doi: 10.1016/j.cell.2013.08.003.

35.

Adrenal gland metastasis is an unusual manifestation of endometrial cancer.

Zaidi SS, Lakhani VT, Fadare O, Khabele D.

Case Rep Surg. 2013;2013:428456. doi: 10.1155/2013/428456. Epub 2013 Aug 6.

36.

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.

Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW.

PLoS One. 2013 Jul 22;8(7):e68915. doi: 10.1371/journal.pone.0068915. Print 2013.

37.

TR3 modulates platinum resistance in ovarian cancer.

Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC, Saskowski J, Crispens MA, Jones HW 3rd, James S, Fadare O, Khabele D.

Cancer Res. 2013 Aug 1;73(15):4758-69. doi: 10.1158/0008-5472.CAN-12-4560. Epub 2013 May 29.

38.

A case of extrauterine endometrial stromal sarcoma in the colon diagnosed three decades after hysterectomy for benign disease.

Ayuso A, Fadare O, Khabele D.

Case Rep Obstet Gynecol. 2013;2013:202458. doi: 10.1155/2013/202458. Epub 2013 Apr 24.

39.

Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas.

Fadare O, James S, Desouki MM, Khabele D.

Ann Diagn Pathol. 2013 Oct;17(5):430-3. doi: 10.1016/j.anndiagpath.2013.04.011. Epub 2013 May 21.

40.

The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.

Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V.

Mod Pathol. 2013 Aug;26(8):1101-10. doi: 10.1038/modpathol.2013.35. Epub 2013 Mar 22.

41.

Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.

Fadare O, Liang SX, Crispens MA, Jones HW 3rd, Khabele D, Gwin K, Zheng W, Mohammed K, Parkash V, Hecht JL, Desouki MM.

Hum Pathol. 2013 Aug;44(8):1508-15. doi: 10.1016/j.humpath.2012.12.003. Epub 2013 Mar 1.

42.

Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Fadare O, Zheng W, Crispens MA, Jones HW, Khabele D, Gwin K, Liang SX, Mohammed K, Desouki MM, Parkash V, Hecht JL.

Am J Cancer Res. 2013;3(1):70-95. Epub 2013 Jan 18.

43.

Salpingo-oophorectomy specimens for endometrial cancer staging: a comparative analysis of representative sampling versus whole tissue processing.

Fadare O, Khabele D.

Hum Pathol. 2013 Apr;44(4):643-50. doi: 10.1016/j.humpath.2012.07.015. Epub 2012 Oct 16.

44.

Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.

Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D.

Gynecol Oncol. 2012 Dec;127(3):579-86. doi: 10.1016/j.ygyno.2012.09.016. Epub 2012 Sep 23.

45.

Near-infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses.

Vargis E, Tang YW, Khabele D, Mahadevan-Jansen A.

Transl Oncol. 2012 Jun;5(3):172-9. Epub 2012 Jun 1.

47.

An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma.

Khabele D, Fadare O, Liu AY, Wilson AJ, Wass E, Osteen K, Crispens MA.

Int J Clin Exp Pathol. 2012;5(1):37-45. Epub 2011 Jan 1.

48.

Sensitivity of Raman spectroscopy to normal patient variability.

Vargis E, Byrd T, Logan Q, Khabele D, Mahadevan-Jansen A.

J Biomed Opt. 2011 Nov;16(11):117004. doi: 10.1117/1.3646210.

49.

The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.

Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D.

Cancer Biol Ther. 2011 Sep 15;12(6):484-93. doi: 10.4161/cbt.12.6.15956. Epub 2011 Sep 15.

50.

Pleomorphic liposarcoma of the uterine corpus with focal smooth muscle differentiation.

Fadare O, Khabele D.

Int J Gynecol Pathol. 2011 May;30(3):282-7. doi: 10.1097/PGP.0b013e31820086a4. Review.

PMID:
21464725

Supplemental Content

Loading ...
Support Center